News

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 26, 2023.

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]

In a 6-month trial, more than 85% of adults on CBD showed significant reduction in the number of monthly seizures, suggesting this treatment may be an effective adjuvant option.

Fifty-four percent of patients with ALS carried at least one detrimental common variant or repeat expansion, highlighting the clinical impact of gene variants as modifiers in ALS.

Thirty days after treatment, a primary-outcome event occurred in 2.9% of those in the early-treatment group and 4.1% of those in the later-treatment group.

Study shows that digital devices can provide objective and real-world measures of Parkinson disease, capturing key motor and nonmotor features of for early diagnosis of the neurodegenerative disorder.

The director of vascular neurology at NYU Langone Hospital in Brooklyn discussed the high prevalence of common risk factors for stroke, emphasizing the importance of early detection and management for prevention. [WATCH TIME: 4 minutes]

Poststroke patients who engaged in at least 4 hours of physical activity per week had a higher likelihood of a mild stroke and had smaller hematoma volumes on admission.

The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]

Robust, sustained reductions in key pharmacodynamic biomarker were observed; however, this did not lead to functional benefits on any of the scales used in the trial.

The head of CRCSEP and coordinator of the Neurosciences Research Unit at Paris City University discussed the positive results of teriflunomide in treating radiologically isolated syndrome, a preclinical stage of multiple sclerosis. [WATCH TIME: 4 minutes]

Submitted under the accelerated approval pathway, if approved, SRP-9001 would become the first marketed gene therapy specific for Duchenne muscular dystrophy.

The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDless trial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]

The senior associate consultant in the Department of Neurology at Mayo Clinic provided insight on an early feasibility study on the clinical impact of microburst vagus nerve stimulation in patients with drug-resistant epilepsy.

In honor of National Stroke Awareness Month, held May 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates.

Females with episodic migraine had higher interictal CGRP concentrations in plasma and the tear fluid during menstruation than females without migraine.

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute discussed the future of treating Parkinson disease psychosis, and potential ways to lower risk of poor long-term outcomes. [WATCH TIME: 3 minutes]

Episode 34 of the AUPN Leadership Minute features Alissa Willis, MD, of University of Mississippi Medical Center; and Merit Cudkowicz, MD, of Mass General Hospital and Harvard Medical School. [WATCH TIME: 4 minutes]

A recent published study highlighted the importance of environmental risk factors for Parkinson disease, such as exposure to trichloroethylene and other volatile organic compounds.

The consultant and founder of Accelerating NeuroVentures talked about the pridopidine arm from the HEALEY ALS Platform trial, which showed significant benefits in speech measures. [WATCH TIME: 5 minutes]

Clinically relevant effect sizes were observed, with those in the highest Dietary Inflammatory Index quartile having relapse risk 2.45 times higher than those in the lowest quartile.

Findings showed that greater average daily step count was significantly correlated with greater C2-C3 spinal cord gray matter areas, total cord area, and cortical gray matter volume.

In honor of ALS Awareness Month, held May 2023, get caught up on some of the latest news in amyotrophic lateral sclerosis as the NeurologyLive® team shares some of our data updates.

The director of vascular neurology at NYU Langone talked about how to identify the signs and symptoms of stroke and the importance of early intervention. [WATCH TIME: 4 minutes]

Asudexian is currently being assessed in a large-scale phase 3 program expected to comprise more than 27,000 patients with atrial fibrillation across over 40 countries.

The senior academic at the University of Sydney provided perspective on the role of CNM-Au8 in MS among a crowded treatment landscape, and the need for adjuvant treatments that address lingering lesion burden. [WATCH TIME: 3 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

To date, in the largest series of patients treated with lacosamide after first-line treatment failure, pain relief was achieved in 66% of patients, with a relatively low proportion of mild adverse events.